A cohort study of the effect of traditional Chinese medicine combined with Western medicine standard treatment on survival of patients with liver metastasis of colorectal cancer.

Abstract

e15537 Background: Based on the results of our team's previous cohort study on metastatic colorectal cancer (mCRC), it can be seen that traditional Chinese medicine (TCM) has unique advantages in the treatment of colorectal cancer with liver metastasis. However, the efficacy and safety of TCM combined with Western medicine standard treatment lacks high-level evidence-based medical evidence support, and has not been widely recognized.This study was to analyze the survival benefits of TCM combined with Western medicine standard treatment in colorectal cancer patients with liver metastases, and to provide reliable evidence-based medical evidence for the treatment of colorectal cancer patients with liver metastases. Methods: In this study, a retrospective cohort design was used, and the exposure factor of patients with colorectal cancer liver metastases (CRLM) was whether they received continuous Chinese medicine treatment for ≥3 months. Those who met these exposure factors entered the integrated traditional Chinese and Western medicine cohort and received the TCM combined with Western medicine standard treatment. Those who did not meet this exposure factor entered the Western medicine cohort and received the standard Western medicine treatment. Overall survival, 3rd and 5th year survival rates and efficacy differences among subgroups were compared between the two cohorts. Results: A total of 79 subjects were included in the integrated traditional Chinese and Western medicine cohort, with a median overall survival (mOS) of 32 months (95%CI 28-40.6), and 124 subjects in the Western medicine cohort, with a mOS of 20.8 months (95%CI 17.3-25.4). The difference was statistically significant ( P = 0.0002, HR = 0.62). The 3rd and 5th year survival rates were 45.57% and 26.58% in integrated traditional Chinese and Western medicine cohort, and 28.23% and 12.90% in Western medicine cohort, respectively. Subgroup analysis showed that there were statistically significant differences between the two groups in the elderly/non-elderly, female, right-half colon, RAS/BRAF wild Type, RAS/BRAF mutation, with/without local therapy, with/without chemotherapy, with/without targeted therapy ( P < 0.05). Conclusions: TCM combined with Western standard treatment can prolong the overall survival and improve the 3rd and 5th year survival rate of patients with liver metastasis of colorectal cancer. Clinical trial information: ChiCTR-IOR-17010497 .